A Study of Tarceva for Use in Patients With Relapsed or Refractory Metastatic Non-Small Cell Lung Cancer

Part of paid clinical trials in Knoxville, Tennessee.

Sponsor
Millennium Pharmaceuticals, Inc.
Study ID
NCT00283634
Phase
PHASE2
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

Tarceva, an orally available small molecule, has demonstrated potent activity in tumor models and humans. This randomized, open-label phase 2 study of Tarceva alone and of Tarceva plus VELCADE is designed primarily to determine the objective tumor response rates to these treatments in patients with Stage IIIB or Stage IV non-small cell lung cancer (NSCLC) that is refractory to or has relapsed after front-line chemotherapy.

Key Dates

First listed
Jan 30, 2006
Start date
Aug 31, 2005
Status verified
Feb 2011
Primary completion
Jul 31, 2007
Completion
Aug 31, 2007

Study Design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Locations (1)

FacilityCityStateZIPSite coordinators
University of TenneseeKnoxvilleTennessee37920-

Find similar trials in Knoxville, TN

By condition
Lung cancer
By specialty
OncologyLung oncologyLung disease
By research site
University of Tennesee· Knoxville, TN

Related Studies